Chaitanya Mandapakala, MD
Pulmonary Disease · Crestview Hills, KYNPI 1568783090
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,083 of the $7,927 with a category attached, or 64.1%. 30 manufacturers reported payments, led by Intuitive Surgical at 38.7% of the total. 2025 is the largest year on record at $3,248, 3.6 times the $911 reported in 2019.
Across 268 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$2K
- AstraZeneca$881
- Boehringer Ingelheim$438
- Siemens Medical Solutions USA, Inc.$191
- Mylan Specialty L.p.$191
- plus $1K from 24 others
What the payments were for
- Travel & lodging$2,78035%
- Food & beverage$5,08364%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $3,068 |
| GSK | 110 | $1,734 |
| AstraZeneca | 38 | $881 |
| Boehringer Ingelheim | 22 | $438 |
| Siemens Medical Solutions USA, Inc. | 1 | $191 |
| Mylan Specialty L.p. | 11 | $191 |
| Veran Medical Technologies, Inc. | 3 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
| Sanofi | 7 | $129 |
| Galvanize Therapeutics, Inc | 1 | $126 |
| Grifols USA, LLC | 7 | $113 |
| Regeneron Healthcare Solutions, Inc. | 5 | $101 |
| Pulmonx Corporation | 4 | $95 |
| Body Vision Medical Inc. | 1 | $85 |
| Actelion Pharmaceuticals US, Inc. | 5 | $82 |
| Sunovion Pharmaceuticals Inc. | 5 | $64 |
| Insmed, Inc. | 2 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Getinge USA Sales, LLC | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Amgen | 1 | $18 |
| Electromed, Inc. | 3 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,795
- NUCALA$240
- Cios Spin$191
- Spin$126
- ALIYA SYSTEM$126
- AREXVY$120
- SHINGRIX$120
How this compares
$7,927 in reported general payments places this provider in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 327 | $307,498 |
| OfevNintedanib Esylate | 14 | $182,077 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $166,228 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $58,886 |
| Dupixent SyringeDupilumab | 13 | $47,104 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $43,753 |
| Spiriva RespimatTiotropium Bromide | 22 | $19,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $15,961 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,224 |
| Pirfenidone | 17 | $9,581 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $7,712 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $5,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 104 | $3,616 |
| Ventolin HfaAlbuterol Sulfate | 13 | $726 |
| MethotrexateMethotrexate Sodium | 16 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,734 | $358,963414 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $438 | $217,13060 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $149 | $166,22813 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $881 | $69,11083 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Crestview Hills
- Neal MoserCrestview Hills$18K
- Sai KonduriCrestview Hills$10K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.